Trazodone
Major depressive disorder (MDD) in adults
Boxed warning
- WARNING: SUICIDAL THOUGHTS and BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [see Warnings and Precautions (5.1) ]. Trazodone is not approved for use in pediatric patients [see Use in Specific Populations (8.4) ]. WARNING: SUICIDAL THOUGHTS and BEHAVIORS See full prescribing information for ... (see full label)
Indications
- Major depressive disorder (MDD) in adults
Adult dosing
- mdd initial: dose: 150; unit: mg; route: PO; interval: daily in divided doses; fixed: true; labelExcerpt: Starting dose: 150 mg in divided doses daily. May be increased by 50 mg per day every three to four days. Maximum dose: 400 mg per day in divided doses (2) .
Pediatric dosing
- Consult pharmacy/current label
Renal adjustment
- Consult pharmacy/current label
Hepatic adjustment
- Use with caution; not studied in patients with hepatic impairment.
Contraindications
- Concomitant use of MAOIs
- Use within 14 days of stopping MAOIs
Clinical pearls
- Maximum, not a dose target (label): inpatients up to but not in excess of 600 mg/day in divided doses
- Take shortly after a meal or light snack to potentially increase absorption.
- Monitor for clinical worsening and suicidal thoughts, especially during initial therapy or dosage changes.
- Gradually reduce dosage upon discontinuation to avoid adverse reactions.
- Avoid use in patients with risk factors for prolonged QT interval or those taking other drugs that increase the QT interval.
Source and review
- DailyMed label (trazodone hydrochloride), Set ID 094ca37b-3ae2-4889-9536-e7e5f20e3105, effective 2026-08-20. Last reviewed: 2026-11-11
RotationRx · Drugs · Scores · Protocols · Diagnoses · Specialties